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Abstract
Objectives
Vitamin D deficiency, which is common worldwide, increases the risks of falls and fractures and can lead to
increased morbidity and mortality. However, the clinical utility and relevance of vitamin D activation remain
unknown. The aim of the present study was to clarify the clinical usefulness of serum 1,25-dihydroxyvitamin
D (1,25D)/25-hydroxyvitamin D (25D) ratio for assessment of the extent of bone metabolism.
Methods
We retrospectively screened data for 87 patients whose serum 1,25D and 25D levels were measured. Eight
patients who were taking vitamin D preparations were excluded, and data for 79 patients (33 males and 46
females) were analyzed. Since menopausal status can be associated with serum vitamin D level, we divided
the patients by gender and divided the female patients into two groups at the age of 50 years.
Results
The median serum 1,25D/25D ratio was significantly lower in males than in females, with the most
considerable difference in all males [4.1 (interquartile range: 2.3-5.8) × 10−3] versus elderly females (aged
≧50 years) [7.9 (3.3-10.1) × 10−3). Main disorders were endocrine (30.6%), inflammatory (18.5%), and bone-
related (16.7%) disorders. The ratios of serum 1,25D/25D had significant negative correlations with femoral
dual-energy X-ray absorptiometry % young adult mean (DEXA %YAM) (R=−0.35) and lumbar DEXA %YAM
(R=−0.32). Significant correlations were found between the 1,25D/25D ratio and serum levels of inorganic
phosphate (iP), parathyroid hormone, and alkaline phosphatase (ALP). The 1,25D/25D ratio had gender-
specific characteristics: the ratio was significantly correlated with age in males (R=−0.49), while it was
significantly correlated with BMI in females (R=0.34).
Conclusions
The results of this study suggested that vitamin D activity is negatively correlated with bone mineral
density, being reduced in aged males but enhanced in obese females.
Categories: Endocrinology/Diabetes/Metabolism, Internal Medicine
Keywords: aging, bone metabolism, calcium, cyp27b1, vitamin d
Introduction
Vitamin D is obtained in the body by food intake or by production from 7-dehydrocholesterol by exposure of
the skin to ultraviolet B radiation [1]. Vitamin D is first metabolized in the liver to 25-hydroxyvitamin D
(25D), which is a major circulating metabolite [1]. In the kidney, 25D is subsequently metabolized to the
hormonally active form, 1,25-dihydroxyvitamin D (1,25D), via 1α-hydroxylase encoded by the CYP27B1
gene [1]. Renal CYP27B1 is regulated primarily by parathyroid hormone (PTH) and calcitonin in stimulatory
manners and by fibroblast growth factor-23 (FGF-23) and 1,25D itself in inhibitory manners [1]. CYP27B1
also exists in extra-renal sites such as macrophages, and its expression in extra-renal sites is associated with
granuloma-forming disorders and is regulated mainly by type I and type II interferons (IFNs) [2]. 1,25D has a
cellular effect through the vitamin D receptor (VDR) [3], which leads to calcium absorption in the gut, bone
metabolism, and parathyroid function.
Serum 25D level has been considered to be a reliable marker of vitamin D status: serum 25D level below 20
ng/mL is defined as vitamin D deficiency and serum 25D level below 30 ng/mL is defined as vitamin D
insufficiency [4]. A recent study showed that a low vitamin D status is common worldwide and is associated
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with various diseases including kidney, heart, and liver failure, secondary hyperparathyroidism,
osteomalacia, inflammatory bowel disease, granuloma-forming disorders (sarcoidosis and tuberculosis), and
cancer [5]. Vitamin D deficiency also increases the risks of falls, fractures, bone loss, and sarcopenia [6-8],
leading to worse outcomes of illness severity, morbidity, and mortality [9-11]. However, since the evaluation
of only serum 25D level did not explain hormonal activity of vitamin D, it is conceivable that we should take
serum 1,25D level into account as well. The clinical utility of and the relevance to pathophysiology of
evaluation of the ratio 1,25D/25D, which indicates the extent of vitamin D activation, have remained
unknown.
In the present study, we retrospectively investigated the relevance of activation of vitamin D to various
clinical characteristics of patients who visited a general medicine department.
Materials And Methods
Study design
We conducted a single-center cross-sectional study: the medical records of 87 patients (male/female: 35/52),
whose serum levels of 25D and 1,25D were measured between January 2017 and December 2019 at the
Department of General Medicine, Okayama University Hospital were screened. Of those patients, 8 patients
(2 males and 6 females) who were taking vitamin D preparations were excluded, and data for 79 patients (33
males (41.8%) and 46 females (58.2%)) were analyzed. The decision to examine serum levels of 25D or 1,25D
had been made individually by physicians for clinical purposes when vitamin D-related disorders such as
hyper- and hypoparathyroidism, osteoporosis, and granuloma-forming disorders were suspected [5]. Data
for other biochemical parameters were obtained within one week from the measurement of 25D or
1,25D. The present study was approved by the Ethical Committee of Okayama University Hospital (KEN-
2001-022) and adhered to the Declaration of Helsinki.
Analysis of clinical parameters
Information on the patients’ main disorders and past medical histories was obtained from hospital medical
records. Information on age, gender, race, body mass index (BMI), and self-rating depression scale (SDS) was
also obtained [12]. Information on the following biochemical parameters was also obtained: white blood
cells, red blood cells, hemoglobin, hematocrit and platelets for blood cell counts; 25D, 1,25D, calcium (Ca),
corrected Ca (cCa), inorganic phosphate (iP), cCa × iP, alkaline phosphatase (ALP), bone-specific alkaline
phosphatase (BAP), and intact PTH for bone metabolism; total bilirubin, total protein, albumin, aspartate
aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), γ-glutamyl
transpeptidase (γGTP), sodium, potassium, chloride, magnesium, blood urea nitrogen (BUN), creatinine and
estimated glomerular filtration rate (eGFR) for liver and renal functions; prothorombin time-international
normalized ratio (PT-INR), activated partial thromboplastin time (APTT), and d-dimer for coagulatory
markers; C-reactive protein (CRP), erythrocyte sedimentation rate in one hour (ESR), ferritin, 50% hemolytic
unit of complement (CH50) and angiotensin-converting enzyme (ACE) for inflammatory markers; and
hemoglobin A1c (HbA1c), plasma glucose, total cholesterol, uric acid, adrenocorticotropic hormone (ACTH),
cortisol, prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), growth hormone (GH),
thyroid-stimulating hormone (TSH), free thyroxine (FT4), ratio of TSH/FT4, and total testosterone for
endocrine and metabolic markers. The levels of those parameters were determined by using an auto-
analyzer system at the Central Laboratory of Okayama University Hospital. The levels of 25D and 1,25D were
determined by a radioimmunoassay and a chemiluminescent immunoassay, respectively, at LSI Medience
Corporation (Tokyo). Radiological data of dual-energy X-ray absorptiometry % young adult mean (DEXA
%YAM) in the femoral bone and lumbar spine were evaluated as we previously reported [13].
Statistical analysis
All statistical analyses were performed using EZR, version 1.40 (Saitama Medical Center, Jichi Medical
University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical
Computing, Vienna, Austria) [14]. In more detail, it is a modified version from R commander designed to add
functions of frequently used statistics in biostatistics. Continuous measurements were statistically tested
using the Mann-Whitney U test, Spearman's rank correlation coefficient, or Kruskal-Wallis test. The Mann-
Whitney U test and Spearman's rank correlation coefficient were treated as two-sided. When differences
were detected by the Kruskal-Wallis test, the Steel-Dwass post-hoc test was used for further analysis
between the groups. P-values less than 0.05 were regarded as statistically significant. There were potential
confounding factors: diseases such as hyperparathyroidism, sarcoidosis, inflammatory bowel disease,
osteoporosis, and osteomalacia or rickets; environmental factors such as seasonal changes, lifestyles related
to sunlight exposure, and nutritional intake; and gender and the human race. Since menopause has been
reported to cause changes in serum vitamin D level and bone metabolism [15], we conducted stratified
analysis by gender and we divided the female patients into two groups at the age of 50 years [16].
Results
Patients’ characteristics and relations to vitamin D activity
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The 79 patients analyzed in the present study included 33 males (41.8%) and 46 females (58.2%). As shown
in Figure 1A, the median age of the male patients was 65 [interquartile range (IQR): 45-74] years and that of
the female patients was 61.5 (IQR: 40.8-71.8) years, and there was no significant difference in the median
ages. The median BMI of males was 21.7 (IQR: 18.6-24.1) kg/m2 and that of females was 22.0 (IQR: 18.9-
24.5) kg/m2, and the difference was not significant (Figure 1B). The median serum 25D level in males was
12.5 (IQR: 8.4-18.6) ng/mL and that in females was 10 (IQR: 7.5-14.5) ng/mL (Figure 1C). The median serum
1,25D level in males was 47 (IQR: 41.0-64.3) pg/mL and that in females was 58 (IQR: 41.0-83.0) pg/mL
(Figure 1D). There was no significant difference between males and females in the level of 25D (Figure 1C)
or 1,25D (Figure 1D), but the median serum 1,25D/25D ratio was significantly lower in males than in
females: the median ratio in males was 4.1 (IQR: 2.3-5.8) × 10−3 and that in females was 6.8 (IQR: 3.0-9.8) ×
10−3 (Figure 1E). Regarding electrolytes, serum cCa, iP, and cCa × iP levels were not significantly different in
males and females (Figure 1F-1H). The median serum levels of cCa were 9.5 (IQR: 9.1-9.9) mg/dL in males
and 9.5 (IQR: 9.2-10.3) mg/mL in females, those of iP were 3.4 (IQR: 2.9-3.9) mg/dL in males and 3.5 (IQR:
2.8-4.0) mg/dL in females, and those of cCa × iP were 31.5 (IQR: 28.6-36.5) (mg/dL)2 in males and 33.3 (IQR:
29.5-38.4) (mg/dL)2 in females.
FIGURE 1: Characteristics of the male and female patients
Age (A), BMI (B) and serum levels of 25D (C), 1,25D (D), 1,25D/25D ratio (E), cCa (F), iP (G), and cCa × iP (H)
are shown. In each panel, the upper horizontal line, lower horizontal line, and horizontal bar of the box
indicate the 75th percentile, 25th percentile, and median, respectively. The horizontal bars outside the box are
the maximum and minimum values within 1.5 times the interquartile range. The X sign within the box
indicates the mean. *P<0.05, a statistically significant difference between the indicated groups (A-H). BMI:
body mass index; cCa: corrected calcium; iP: inorganic phosphate; n.s.: not significant; 1,25D: 1,25-
dihydroxyvitamin D; 25D: 25-hydroxyvitamin D.
The patients' main disorders and past medical histories are shown in Table 1. The most frequent main
disorders were endocrine disorders (30.6%, 33 of 108 disorders) including primary hyperparathyroidism
(10.2%, 11/108) and ectopic hyperparathyroidism (2.9%, 2/108) for vitamin D-related disorders followed by
inflammatory disorders (18.5%, 20/108) including sarcoidosis (2.8%, 3/108) and inflammatory bowel disease
(2.8%, 3/108) and bone-related disorders including osteoporosis (13.9%, 15/108) and osteomalacia or rickets
(2.8%, 3/108) (Table 1, left). The most frequent past medical history was malignancy (26.8%, 19 of 71
histories) followed by bone-related diseases (16.9%, 12/71) including fractures (11.3%, 8/71) and
osteoporosis (5.6%, 4/71), metabolic diseases (14.1%, 10/71), and ureterolithiasis (11.3%, 8/71) (Table
1, right). Past medical histories possibly related to vitamin D deficiency included sarcoidosis (1.4%, 1/71) in
inflammatory diseases (8.5%, 6/71), while there was no past history of hyper- or hypoparathyroidism (Table
1, right).
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Main disorders Past medical histories
Categories Total (%) Categories Total (%)
Endocrine disorder 33 (30.6) Malignancy 19 (26.8)
Inflammatory disorder 20 (18.5) Bone-related disease 12 (16.9)
Bone-related disorder 18 (16.7) Metabolic disease 10 (14.1)
Mental disorders 10 (9.3) Ureterolithiasis 8 (11.3)
Gastroenterological 9 (8.3) Inflammatory disease 6 (8.5)
Bacterial infection 6 (5.6) CNS-related disease 5 (7.0)
Haematological 4 (3.7) Mental disease 5 (7.0)
Malignancy 2 (1.9) Endocrine disease 4 (5.6)
Other 6 (5.6) Other 2 (2.8)
Total 108 (100) Total 71 (100)
TABLE 1: Main disorders and past medical histories
CNS: central nervous system.
Gender-dependent differences of vitamin D activity and bone mineral
density
Since menopausal status has been reported to be associated with vitamin D and bone metabolism [15], we
divided the female patients into two groups at the age of 50 years [16]. Serum 1,25D/25D ratios were found to
be significantly higher in female patients aged ≧50 years (median ratio, 7.9 (IQR: 3.3-10.1) × 10−3) than in
male patients (median ratio, 4.1 (IQR: 2.3-5.8) × 10−3) (Figure 2A). Regarding bone mineral density, female
patients aged ≧50 years had significantly lower values of DEXA %YAM in both the femoral bone (Figure 2B)
and lumbar spine (Figure 2C) than those in male patients. The median values of DEXA %YAM in male
patients were 84% (IQR: 74-92%) in the femoral bone and 98% (IQR: 83.5-108%) in the lumbar spine, and
those in female patients aged ≧50 years were 63% (IQR: 55.8-72.8%) in the femoral bone and 72% (IQR: 64-
87%) in the lumbar spine.
FIGURE 2: Gender-dependent differences of serum 1,25D/25D ratio and
bone mineral densities
Serum 1,25D/25D ratio (A) and bone mineral densities in the femoral bone (B) and lumbar spine (C) were
compared between male patients, female patients aged <50 years, and female patients aged ≧50 years. The
details of each panel are shown in the legend of Figure 1. **P<0.01 and *P<0.05, statistically significant
correlations between the indicated factors. 1,25D: 1,25-dihydroxyvitamin D; 25D: 25-hydroxyvitamin D; DEXA
%YAM: dual-energy X-ray absorptiometry % young adult mean.
Relationships of serum 1,25D/25D ratios with clinical markers in bone
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metabolism
We investigated the correlations of serum 1,25D/25D ratios with various clinical parameters. Of note, as
shown in Figure 3, 1,25D/25D ratios had significant negative correlations with bone mineral densities
including femoral DEXA %YAM (R=−0.35, *P<0.05; Figure 3A) and lumbar DEXA %YAM (R=−0.32,
*P<0.05; Figure 3B). Regarding biochemical markers of bone metabolism, 1,25D/25D ratios were not
correlated with serum albumin (R=0.19, P=0.13; Figure 4A) and cCa (R=0.17, P=0.18; Figure 4B) levels. On
the other hand, 1,25D/25D ratios had significant positive correlations with serum levels of iP (R=−0.34,
**P<0.01; Figure 4C), intact PTH (R=0.64, **P<0.01; Figure 4D), ALP (R=0.46, *P<0.05; Figure 4E), and BAP
(R=0.62, **P<0.01; Figure 4F). 1,25D/25D ratios had significant negative correlations with creatinine
(R=−0.26, *P<0.05; Figure 4G) and FT4 (R=−0.28, *P<0.05; Figure 4H). The correlations of 1,25D/25D ratios
with other clinical parameters are summarized in Table 2. There were no significant correlations of
1,25D/25D with SDS of the patients' profile, blood cell count, liver function, coagulatory markers,
inflammatory markers, and endocrine and metabolic markers (Table 2).
FIGURE 3: Correlations of serum 1,25D/25D ratio with bone mineral
densities
Correlations of femoral DEXA %YAM (A) and lumbar DEXA %YAM (B) with a 1,25D/25D ratio in all patients are
shown. *P<0.05, statistically significant correlations between the indicated factors (A, B). 1,25D: 1,25-
dihydroxyvitamin D; 25D: 25-hydroxyvitamin D; DEXA %YAM: dual-energy X-ray absorptiometry % young
adult mean.
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FIGURE 4: Relationships of 1,25D/25D ratio with bone metabolism and
clinical characteristics
Correlations of serum 1,25D/25D ratios with albumin (A), cCa (B), iP (C), intact PTH (D), ALP (E), BAP (F),
creatinine (G), and FT4 (H) are shown. **P<0.01 and *P<0.05, statistically significant correlations between the
indicated factors. ALP: alkaline phosphatase; BAP: bone-specific alkaline phosphatase; cCa: corrected
calcium; FT4: free thyroxine; iP: inorganic phosphate; n.s.: not significant; 1,25D: 1,25-dihydroxyvitamin D;
PTH: parathyroid hormone; 25D: 25-hydroxyvitamin D.
Comparison All patients with 1,25D/25D
Patients' profile Number R P-values
Age 79 −0.10 0.43
BMI 79 0.26 *0.036
SDS 41 −0.11 0.56
Blood cell count
   White blood cell 78 −0.21 0.094
   Red blood cell 78 0.16 0.21
   Hemoglobin 78 0.098 0.45
   Hematocrit 78 0.16 0.22
   Platelet 78 −0.12 0.34
Bone metabolism
   Ca 78 0.18 0.16
   cCa 77 0.17 0.18
   iP 69 −0.34 **0.0081
   cCa × iP 68 −0.24 0.065
   ALP 36 0.46 *0.012
   BAP 17 0.62 *0.0098
   Intact PTH 30 0.64 **0.00029
Liver and renal functions
   Total bilirubin 68 0.00027 1.0
   Total protein 70 0.059 0.66
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   Albumin 78 0.19 0.13
   AST 74 −0.038 0.77
   ALT 76 −0.046 0.72
   LDH 75 −0.093 0.47
   γGTP 74 −0.052 0.70
   Sodium 79 0.020 0.88
   Potassium 79 0.093 0.47
   Chloride 79 0.15 0.25
   Magnesium 57 0.27 0.063
   BUN 78 −0.22 0.083
   Creatinine 79 −0.26 *0.036
   eGFR 78 0.11 0.38
Coagulatory markers
   PT-INR 38 −0.28 0.10
   APTT 37 −0.24 0.16
   D-dimer 30 −0.11 0.60
Inflammatory markers
   CRP 72 −0.24 0.067
   ESR 29 −0.073 0.73
   Ferritin 30 −0.12 0.56
   CH50 22 −0.11 0.63
   ACE 27 0.055 0.79
Endocrine and metabolic markers
   HbA1c 48 −0.089 0.58
   Plasma glucose 55 0.24 0.12
   Total cholesterol 61 0.16 0.26
   Uric acid 72 −0.06 0.65
   ACTH 30 −0.30 0.15
   Cortisol 31 0.077 0.72
   PRL 15 −0.40 0.18
   LH 17 0.16 0.56
   FSH 18 0.28 0.28
   GH 18 −0.28 0.29
   TSH 62 −0.12 0.40
   FT4 60 −0.28 *0.047
   TSH/FT4 60 0.042 0.77
Bone mineral density
   DEXA %YAM (Femoral) 49 −0.35 *0.023
   DEXA %YAM (Lumbar) 49 −0.32 *0.039
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TABLE 2: Correlations between serum 1,25D/25D ratio and clinical parameters in all patients
ACE: angiotensin-converting enzyme; ACTH: adrenocorticotropic hormone; ALP: alkaline phosphatase; ALT: alanine aminotransferase; APTT:
activated partial thromboplastin time; AST: aspartate aminotransferase; BAP: bone-specific alkaline phosphatase; BMI: body mass index; BUN:
blood urea nitrogen; CH50: 50% hemolytic unit of complement; Ca: calcium; cCa: corrected calcium; CRP: C-reactive protein; DEXA %YAM: dual-
energy X-ray absorptiometry % young adult mean; eGFR: creatinine and estimated glomerular filtration rate; ESR: erythrocyte sedimentation rate in
one hour; FSH: follicle-stimulating hormone; FT4: free thyroxine; γGTP: γ-glutamyl transpeptidase; GH: growth hormone; HbA1c: hemoglobin A1c;
iP: inorganic phosphate; LDH: lactate dehydrogenase; LH: luteinizing hormone; PRL: prolactin; PTH: parathyroid hormone; PT-INR: prothrombin
time-international normalized ratio; SDS: self-rating depression scale; TSH: thyroid-stimulating hormone; 25D: 25-hydroxyvitamin D; 1,25D: 1,25-
dihydroxyvitamin D.
Relevance of serum 1,25D/25D ratios to patients' age and BMI
1,25D/25D ratio did not show a significant correlation with age in all patients (R=−0.10, P=0.43; Figure
5A). However, when the patients were divided by gender, there was a significant correlation of 1,25D/25D
ratio with age in male patients (R=−0.49, **P<0.01; Figure 5B), but there was no significant correlation in
female patients (R=0.21, P=0.22; Figure 5C). 1,25D/25D ratio showed a significant positive correlation with
BMI in all patients (R=0.26, *P<0.05; Figure 5D). When the patients were divided by gender, there was no
significant correlation in male patients (R=0.13, P=0.51; Figure 5E), but there was a significant correlation in
female patients (R=0.34, *P<0.05; Figure 5F).
FIGURE 5: Correlations of patients' age and BMI in relation to serum
1,25D/25D ratio
Correlations of age with serum 1,25D/25D ratio in all patients (A), male patients (B), and female patients (C)
are shown. Correlations of BMI with serum 1,25D/25D ratio in all patients (D), male patients (E), and female
patients (F) are also shown. **P<0.01 and *P<0.05, statistically significant correlations between the indicated
factors. BMI: body mass index; 1,25D: 1,25-dihydroxyvitamin D; 25D: 25-hydroxyvitamin D.
Discussion
The results of the present study suggested that vitamin D activities had relevance to clinical parameters,
especially bone turnover, with gender-specific correlations with features in age and BMI. The ratio of serum
1,25D/25D as a marker for activation of vitamin D was significantly lower in male patients than in female
patients, particularly in older females (≧50 years of age), who are considered to be menopausal women. On
the other hand, bone mineral density was significantly lower in older female patients (≧50 years of age) than
in male patients. The serum 1,25D/25D ratio was found to be negatively correlated with bone mineral
density, negatively correlated with serum inorganic phosphate, and positively correlated with intact PTH,
ALP, and BAP in all patients. Of interest, the ratio was negatively correlated with age in male patients but
was positively correlated with BMI in female patients, suggesting that vitamin D activation is involved in
bone metabolism in a gender-specific manner.
The 1,25D/25D ratio is a putative index of CYP27B1 activity and is considered to be a useful tool for the
diagnosis of ocular sarcoidosis [17]. In cases of sarcoidosis or lymphomas, type II IFN enhances the activity
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of 1α-hydroxylase in macrophages, resulting in increased production of 1,25D and
hypercalcemia [1]. Excessive vitamin D activity also has a stimulatory effect on bone turnover and an
inhibitory effect on bone mineralization [18]. Vitamin D is a key component of the bone-kidney-parathyroid
endocrine axis. 1,25D produced in the kidney binds to VDR in the bone and also activates FGF-23 gene
expression. Secreted FGF-23 acts on the Klotho-FGF receptor complex in the kidney and parathyroid
gland. In the kidney, FGF-23 down-regulates the Cyp27b1 gene and up-regulates the Cyp24 gene, resulting
in suppression of vitamin D activity. In the parathyroid gland, FGF-23 suppresses the expression of PTH,
which has the potential function of promoting Cyp27b1 gene expression. Since there is a closed negative
feedback loop for vitamin D homeostasis, disruption of the loop regulating CYP27B1 induction results in an
increase in 1,25D level [19-21].
Vitamin D level in serum has been reported to decline with aging due to a reduction in the production of
vitamin D in the skin [22,23]. In general, a hormonal decline of sex steroids such as androgen and estrogen is
important in the aging process [24]. Total testosterone level has been reported to have a slight but
significant positive association with serum 25D level, suggesting that both testosterone and vitamin D can
be health-related markers for males [25]. A meta-analysis showed that vitamin D status has an inverse
relationship with BMI in both diabetic and non-diabetic subjects [26]. Another meta-analysis showed that
serum vitamin D level had an inverse association with the risk of abdominal obesity in a dose-response
manner [27]. Vitamin D deficiency has been considered to be associated with obesity and metabolic
dysregulation by modulating the expression of genes related to adipogenesis and inflammatory and
oxidative stress in mature adipocytes [28].
In the present study, it was also shown that serum levels of creatinine and free thyroxin were negatively
correlated with the serum 1,25D/25D ratio. In this regard, patients with chronic kidney disease (CKD) usually
have secondary hyperparathyroidism and a low serum 1,25 level [29]. Patients in an advanced stage of CKD
have high levels of serum FGF-23 and PTH and a low level of Klotho expression, so-called FGF-23 resistance,
leading to impaired activation of vitamin D [19]. Vitamin D also acts on the thyroid through VDR; however,
there is no clear consensus about a relationship between vitamin D status and thyroid function in healthy
humans [30], although a study on the role of vitamin D in thyroid diseases indicated that vitamin D
deficiency might be an increased risk of autoimmune thyroid diseases [30]. However, based on the present
findings, it seems likely that thyroid function is involved in the activation of vitamin D.
Vitamin D activity should be evaluated when vitamin D-related disorders such as hyperparathyroidism or
granuloma-forming disorders are suspected. However, our findings presented here indicate the importance
of assessing vitamin D activity from the ratio of 1,25D to 25D in general clinical settings. Considering that
vitamin D activation can be linked to aging and obesity as well as bone mineral metabolism, measurement of
serum 1,25D/25D ratio can be useful for suspecting bone loss, fractures, sarcopenia, or other clinical
outcomes associated with frailty. Since the present study showed a negative correlation between serum
1,25D/25D ratio and bone mineral density, serum 1,25D/25D ratio might be a marker for determining the
necessity for vitamin D supplementation. However, when a high serum 1,25D/25D ratio is related to
increased PTH as in primary hyperparathyroidism, vitamin D supplementation may promote the progression
of hypercalcemia. Nevertheless, our findings suggest that a high serum 1,25D/25D ratio is a clue for
considering the loss of bone mineral density. There are some limitations of the present study. Patients
included in the present study had various pathological conditions possibly associated with hypovitaminosis
D. Since we focused on BMI and age, which are physiological parameters potentially influenced by
pathological conditions, our study could not show a direct interrelationship between vitamin D metabolism
and BMI/age. However, we consider that it is meaningful to assess real-world data obtained from clinical
practice in general medicine. Also, serum vitamin D levels can be affected by seasonal changes, lifestyles
related to sunlight exposure, nutritional intake, and human race [5,23]. In the present study, serum vitamin
D levels might have been affected by seasonal changes or sunlight exposure. All of the patients included in
this study were Japanese.
Technically, although free vitamin D and albumin-bound vitamin D (10-15%) are bioavailable, current assays
cannot distinguish free vitamin D from vitamin D-binding protein-bound (DPB) vitamin D (85-90%) and
albumin-bound vitamin D, the amounts of which are affected by the capability for DPB and albumin
synthesis [31]. Another limitation of this study is that it was performed retrospectively at a single center
with a relatively small number of patients, and it is, therefore, difficult to draw a solid conclusion. To clarify
the precise interaction between vitamin D activity and bone turnover, another study with a larger sample
size including a general population or a prospective study using age- and gender-matched cohorts as a
multi-center study will be needed.
In the present study, it was notable that the 1,25D/25D ratio is conceivably a useful tool for suspecting bone
loss, fractures, or other clinical outcomes associated with frailty.
Conclusions
The results of analysis of data for patients in our general medicine department collectively showed that
increased activation of vitamin D is likely to be linked to disruption of the bone-kidney-parathyroid
endocrine axis. Our findings imply the probable existence of a gender-specific difference of aging males and
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obese females regarding the activation of vitamin D that is functionally linked to bone metabolism.
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